skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Datamonitor attended the Jefferies 2012 Global Healthcare Conference held in London over November 14–15, 2012.


This analysis review covers the key highlights of the conference:

Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS


The status of late-stage agents such as Roche’s Perjeta (pertuzumab) for breast cancer, Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec + insulin aspart) for type 2 diabetes, ImmunoGen’s trastuzumab emtansine (TDM1) for breast cancer, Rigel’s fostamatinib for rheumatoid arthritis, Aegerion’s lopidomide for homozygous familial hypercholesterolemia, NPS Pharmaceuticals’ Gattex (teduglutide) for short bowel syndrome and Natpara (recombinant human parathyroid hormone [1-84]) for the treatment of adult hypoparathyroidism, Cubist’s ceftolozane/tazobactam for complicated urinary tract infections and complicated intra-abdominal infections, and United Therapeutics’ implantable infusion.


Download our White Paper for the full analyst review.





電話:+81 (0)3 6273 4260